TACROLIMUS GENOTYPING (CYP3A5)

The association between the CYP3A5 genotype and tacrolimus pharmacokinetics is well established, and patients expressing functional CYP3A5 (carriers of the CYP3A5*1 allele; extensive metabolizer), require approximately double the starting drug dose. Carriers of CYP3A5*3/*3 or poor metabolizer require higher doses.

  • Test Type:
  • Pre-test Information:
    No Special preparation required
  • Report Delivery:
    Sample by Mon/Thu 11 am; Report Wed / Sat
  • Components:
    0

Sample Report